报价延迟最少15分钟:2026/01/07 16:05 EST
盘后时段
|
||||
|
7.6 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.6
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.26/0.88
|
|
企业价值
271.39M
|
| 资产负债 |
|
每股账面净值
-0.13
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
47.54M
|
|
每股收益
0.19
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States. |
